NASDAQ: RLMD

Relmada Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for RLMD. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:59 UTC.

What Relmada Therapeutics, Inc. does

Relmada Therapeutics is a clinical-stage biotechnology company that underwent a strategic review in late 2024 and early 2025, concluding that its best path forward was to acquire new development candidates rather than continue its previous programs. The company terminated work on esmethadone and a psilocybin formulation, and now focuses on two lead products: NDV-01, a novel controlled-release bladder cancer treatment currently in Phase 2 trials, and sepranolone, a neurosteroid acquired from Asarina Pharma for potential treatment of neurological conditions.

Summarized from Relmada Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-05-28
Return on equity	110.71%

Charts

Charts are in the appInteractive charts for RLMD are available in Oxford Ledge.
Open RLMD in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-11

2026-09-11Chief Financial OfficerPurchase120,200$504.8K
2026-09-11Chief Executive OfficerPurchase100,000$418.0K
2026-09-11Chief Executive OfficerPurchase100,000$410.0K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Jupiter Topco LLC11,164,803$77.32MNEW
BlackRock, Inc.7,426,780$51.39M+475.9%
Squadron Capital Management LLC7,350,000$50.86M-13.3%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-12-15Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-05-12AuditorChanges in registrant's certifying accountantMarcumAuthoritativeSEC 8-K →
2025-01-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
globenewswire.com2026-07-16
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Relmada Therapeutics, Inc. do?

When did RLMD last file with the SEC?

Relmada Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-28. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:59 UTC. This page is also available as JSON at /api/data?ticker=RLMD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RLMD and 5,000+ tickers.

Create a free account — keep RLMD

For your agent

GET /api/data?ticker=RLMD

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt